Shukra Pharmaceuticals Ltd Fair Value
SHUKRAPHAR · Healthcare · Current price ₹32.84
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹2 | 15% ROE fading to 12% over ~10 yrs, on ₹2 book |
| Relative P/E | ₹166 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹14 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is Shukra Pharmaceuticals Ltd undervalued?
DocStoX estimates the fair value of Shukra Pharmaceuticals Ltd at ₹50 per share, versus the current market price of ₹33. That puts the stock about +52.3% below our fair-value estimate, which we read as "Strong Buy". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹2), Relative P/E (₹166), Graham floor (₹14). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹2 (bear) to ₹50 (base) to ₹166 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Shukra Pharmaceuticals Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.